Short

According to a recent survey conducted by ZoomRx, two-thirds of the 20 largest pharmaceutical companies prohibit their employees from using ChatGPT due to security concerns regarding sensitive internal data. Nevertheless, many life sciences professionals use ChatGPT regularly, even though 83 percent say the technology is "overrated." Despite the potential for increased efficiency and effectiveness through the use of AI in drug development, the majority of pharmaceutical companies are cautious about the technology due to security risks. Most companies see AI primarily as a means to reduce costs, while concerns about data security and privacy remain. But there are exceptions. According to OpenAI, Moderna is using ChatGPT in a pilot project called Dose ID to analyze and visualize large data sets and determine the optimal vaccine dose.

Short

Japan is considering creating a new dialogue forum with like-minded nations to discuss global regulations for the responsible use of generative AI technology. Prime Minister Fumio Kishida is expected to make an announcement at an OECD ministerial meeting in Paris in early May, according to Mainichi's sources. Japan aims to build broader support for the "Hiroshima AI Process," a G7 initiative to discuss global rules for AI. As generative AI tools such as ChatGPT rapidly advance, there is growing concern that misinformation spread by AI misuse could threaten democracy and political stability. By taking a leading role in international regulation of AI, Japan hopes to promote both the development and oversight of the technology. The non-binding guidelines agreed at the G7 summit in Hiroshima aim to promote the creation of safe and trustworthy AI systems.

Ad
Ad
Ad
Join our community
Join the DECODER community on Discord, Reddit or Twitter - we can't wait to meet you.
Ad
Join our community
Join the DECODER community on Discord, Reddit or Twitter - we can't wait to meet you.
Google News